Abu Abraham, M.D.’s appointment as Chief Medical Officer
We are pleased to announce that Abu Abraham, M.D. has joined as the group’s Chief Medical Officer. Dr. Abu Abraham has over 20 years of working experience in the pharmaceuticals and medical area. He formerly served as Vice President and Global Head of Retina and Vitreous Therapeutics at Santen, where he managed a […]
New drug CBT-009 approved to conduct Phase I/II clinical trial in Australia
We are pleased to announce that Australia regulatory agency has approved our application to conduct Phase I/II trial in Australia to evaluate safety, tolerability and pharmacodynamics of CBT-009 (atropine) on healthy volunteers. Clinical trial is scheduled to start in July 2022. Myopia is a common visual disorder and has become the major cause of visual […]
Dr. Jinsong Ni awarded Shishan Technology Innovation and Entrepreneurship “Leading Talent” title
Jinsong Ni, Ph.D, founder and CEO of Cloudbreak Pharma, has been recently awarded the title of Shishan Technology Innovation and Entrepreneurship “Leading Talent” in Suzhou High-tech Zone for 2022. Dr. Ni is the founder of Cloudbreak Pharma. He leads an R&D team that is composed of R&D experts from Allergan, the Fortune 500 […]
Cloudbreak Pharma joins Ophthalmology Tech Summit 2022
We are thrilled to participate in and be an Event Sponsor of the Ophthalmology Tech Summit 2022, which will be held on June 16-17 at Balboa Bay Resort, California. 54 speakers and over 80 KOLs will gather in the event to engage with ophthalmologists, industry leaders and entrepreneurs to share the industry developments and innovations […]
Ms. Rebecca Chan, a former senior executive of the Listing Division of the Hong Kong Stock Exchange and ex-partners of three out of four big four international firms, joins Cloudbreak Pharma as the Chief Financial Officer
Cloudbreak Pharma is pleased to announce that Ms. Rebecca Chan has joined as the group’s Chief Financial Officer. Rebecca’s contributions will be instrumental to Cloudbreak Pharma’s future development. Ms. Rebecca Chan has over 34 years of working experience in international accounting firms and the Hong Kong Stock Exchange. She has served as a partner of […]
Cloudbreak completed Phase II Clinical Trial for CBT-006 in the U.S. for the treatment of Meibomian Gland Dysfunction associated Dry Eye Disease
Cloudbreak Pharma has announced that the last patient has exited the study of the Phase II clinical trial in the U.S on May 17, 2022 for CBT-006, a new drug for the treatment of dry eye disease caused by meibomian gland dysfunction. The results of the Phase II clinical trial are expected to be officially […]
Cloudbreak Receives U.S. Food and Drug Administration Clearance to Proceed with Clinical Study using Investigational New Drug CBT-004
Irvine, CA – February 18, 2021 – Cloudbreak Therapeutics, a clinical-stage company focused on developing innovative therapies for diseases and conditions of the eye, had received clearance from the U.S. Food and Drug Administration (FDA) to proceed with a Phase 2 study using Investigational New Drug (IND) CBT-004 to treat vascularized pinguecula. The Phase 2 […]
Cloudbreak Receives U.S. Food and Drug Administration Clearance to Proceed with Clinical Study using Investigational New Drug CBT-006
Irvine, CA – November 30, 2020 – Cloudbreak Therapeutics, a clinical-stage company focused on developing innovative therapies for diseases and conditions of the eye, had received clearance from the U.S. Food and Drug Administration (FDA) to proceed with a Phase 2 study using Investigational New Drug (IND) CBT-006 to treat Meibomian Gland Dysfunction Associated Dry […]